Clinical Trials Sponsored by Pila Pharma

Total 9410 results

Pila Pharma

Completed

A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2

Denmark
Pila Pharma
Biomapas

Completed

A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes

Diabetes Mellitus, Type 2 | Pharmacokinetics | Efficacy | Safety

Lithuania
Chinese PLA General Hospital
Roche Pharma AG

Completed

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Malignant Pleural Effusion

China
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
PT Sydna Farma
PT Pharma Metric Labs

Completed

Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers

Drug Use

Indonesia
Monash University
Caring Pharmacy; Bionime Corporation; Tigas Pharma

Active, not recruiting

Prevention and Treatment of Diabetes in Adults

PreDiabetes

Malaysia
Centro Hospitalar de Vila Nova de Gaia/Espinho,...
LEO Pharma; Diagnostica Stago

Unknown

Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients (FIIT_Score)

Cancer | Thrombosis | Biomarkers | Thromboembolism

Portugal
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
NicOx
Theradis pharma; Iris Pharma

Withdrawn

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (Goldeneye)

Adenoviral Conjunctivitis

Spain
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
Astellas Pharma Inc
Advanz Pharma

Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter

United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
Vifor Pharma, Inc.

Recruiting

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Hyperkalemia

United States, Israel
Vifor Pharma, Inc.

Terminated

FDDA Utilization Study (FDDAU)

Fatigue

Switzerland
UCB Pharma SA

Completed

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (NexT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic

Poland, Sweden, Hungary, Czechia
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain
UCB Pharma SA

Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Epilepsy | Partial Seizures

China
UCB Pharma GmbH

Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Epilepsy

France, United States, Mexico, Turkey, Belgium, Germany
UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
UCB Pharma GmbH

Completed

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch (NON-GI)

Idiopathic Parkinson's Disease

Germany
Astellas Pharma Inc
Advanz Pharma

Completed

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation (ACT 4)

Atrial Fibrillation

United States, South Africa, Canada, Argentina, Denmark, Sweden
UCB Pharma SA

Completed

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Narcolepsy With Cataplexy

Belgium
UCB Pharma SA

Completed

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Epilepsy

United States, France, Germany, Spain, United Kingdom
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Epilepsy

Ukraine, Belgium, Germany, Hong Kong, India, South Africa, Taiwan, Sweden, Korea, Republic of, Singapore, Russian Federation, Austria, Italy, Norway, Czechia
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
Astellas Pharma Inc
Astellas Pharma US, Inc.; Advanz Pharma

Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Atrial Fibrillation | Atrial Flutter

Poland, United States, Canada, Argentina, Denmark, India
PT Kalbe Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of 20 mg Omeprazole Capsules in Indonesia Healthy Subject

Drug Use

Indonesia
University of Medicine and Pharmacy Craiova
Fiterman Pharma SRL

Unknown

Complex Imaging Assessment of Steatosis (SteatoSPC)

Fatty Liver

Romania

3

Subscribe